With circa $250M cash, a Globally strong partner ( why else...

With circa $250M cash, a Globally strong partner ( why else would TEVA announce a $3bn share buyback) and manufacturing(Lonza) put away, there is lots to look fwd to in 2012; including

(1)UPDATES on Phase II trials including;
- Completion of 60 patient Spinal Fusion trials (Lumbar 24 & Cervical 36).
- Progress on 100 patient Intervertebral disk trials. The Global mkt for this application is huge ($42bn) and only ranks 3rd behind CHF ($57bn) and Diabetes($259bn) in MSB's pipeline..[per Merrill's initiating coverage in early Nov 2011).
- Completion of 24 patient Knee Ostreoarthiritis trials.

(2) MORE news and updates on the commencement of Phase II(FDA approved) Trials , including
- The Eyes (wet age-related macular degeneration
- 225 patient Heart Attack Trials

(3) UPDATES on Progession to Phase II trials for
- Chronic Angina
- Diabetes
- Other intraveneous products

(4) BMT trials and 1st patient in Phase III.
Hope this one progresses quickly as simply no other current treatment available and effective (IMO , will be a milestone event for the company).

Looking at the above, I can understand why many analysts predict more M & A Activity in 2012.

Finally...VERY excited about the Phase II CHF results and progession there of. Excluding comments by u know who, there were many positive articles written around the 15th November. But I came across one ( Pharmasentry & dated 16 Nov 2011 ) which provided more information to me than others. The reference is posted below:

http://www.pharmasentry.com/news/newsletter.cfm?linkid=B2F16D76-1372-54C2-61716740682419CD.

I know we have heard it all before but still very powerful and notable comments by Dr Perin ( Texas Heart Institute Director) and even more pleasant cherring words from our CEO about TEVA.

Happy new year to all holders , best of health and good luck to all holders.

Here's to 2012 !!